Skip NavigationSkip to Content

CpG DNA as a vaccine adjuvant

  1. Author:
    Bode, C.
    Zhao, G.
    Steinhagen, F.
    Kinjo, T.
    Klinman, D. M.
  2. Author Address

    [Bode, C; Zhao, G; Steinhagen, F; Kinjo, T; Klinman, DM] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA;Klinman, DM (reprint author), NCI, Canc & Inflammat Program, Frederick, MD 21702 USA;klinmand@mail.nih.gov
    1. Year: 2011
    2. Date: Apr
  1. Journal: Expert Review of Vaccines
    1. 10
    2. 4
    3. Pages: 499-511
  2. Type of Article: Review
  3. ISSN: 1476-0584
  1. Abstract:

    Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.

    See More

External Sources

  1. DOI: 10.1586/erv.10.174
  2. WOS: 000290834400017

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel